A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

May 18, 2023

Primary Completion Date

January 30, 2026

Study Completion Date

March 31, 2027

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

Cetrelimab

Cetrelimab will be administered as IV infusion.

DRUG

Amivantamab

Amivantamab will be administered as IV infusion.

Trial Locations (44)

8028

Hosp. Univ. Quiron Dexeus, Barcelona

10043

Aou San Luigi Gonzaga, Orbassano

20141

European Institute of Oncology, Milan

20162

ASST Grande Ospedale Metropolitano Niguarda, Milan

22031

Virginia Cancer Specialists, Fairfax

28041

Hosp. Univ. 12 de Octubre, Madrid

34147

Bakirkoy Sadi Konuk Training and Research Hospital, Istanbul

34722

Goztepe Prof Dr Suleyman Yalcin Sehir Hastanesi, Istanbul

35170

Medicana International Izmir, Izmir

37134

Centro Ricerche Cliniche di Verona S r l, Verona

41009

Hosp. Virgen Macarena, Seville

46009

Instituto Valenciano de Oncologia, Valencia

54100

Sakarya University Training and Research Hospital, Sakarya

59100

University Malaya Medical Centre, Kuala Lumpur

77030

MD Anderson Cancer Center, Houston

90720

Cancer and Blood Specialty Clinic, Los Alamitos

91010

City of Hope, Duarte

92618

City of Hope Orange County Lennar Foundation Cancer Center, Irvine

93586

Hospital Umum Sarawak, Kuching

97213

Providence Portland Medical Center, Portland

97225

Providence Oncology and Hematology Care Clinic Westside, Portland

14784 400

Fundacao Pio XII, Barretos

30110 022

Cetus Oncologia, Belo Horizonte

30130 090

PERSONAL Oncologia de Precisao e Personalizada, Belo Horizonte

80810 050

CIONC Centro Integrado de Oncologia de Curitiba, Curitiba

86015 520

Hospital do Cancer de Londrina, Londrina

91350 200

Hospital Nossa Senhora da Conceicao S A, Porto Alegre

40050-410

Hospital Santa Izabel Santa Casa de Misericordia da Bahia, Salvador

01509 900

Fundacao Antonio Prudente A C Camargo Cancer Center, São Paulo

20 609

INSTYTUT GENETYKI I IMMUNOLOGII GENIM Sp z o o, Lublin

60 569

Wielkopolskie Centrum Pulmonologii i Torakochirurgii im. Eugenii i Janusza Zeylandow, Poznan

02 781

Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy, Warsaw

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital Yonsei University Health System, Seoul

06351

Samsung Medical Center, Seoul

03010

Hosp. Gral. Univ. de Alicante, Alicante

08035

Hosp Univ Vall D Hebron, Barcelona

01170

Adana City Hospital, Adana

06200

Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara

06800

Ankara Bilkent City Hospital, Ankara

Ankara Bilkent City Hospital, Çankaya

W6 8RF

Imperial College London and Imperial College Healthcare NHS Trust, London

NE7 7DN

Freeman Hospital, Newcastle

SM2 5PT

Royal Marsden Hospital, Sutton

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT05908734 - A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter